European Pharmaceutical Review

MARCH 4, 2024

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Food and Drug Administration 88

Food and Drug Administration Transportation FDA Medical 88

European Pharmaceutical Review

JANUARY 19, 2023

The additional support from Amgen is set to reach more than 300 diverse and community-oriented clinical investigators by 2027. Currently close to 80 percent of participants in clinical research trials are white, according to the Food and Drug Administration (FDA).

Food and Drug Administration 80

Food and Drug Administration Physicians Medicine Food 80

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics.

Food and Drug Administration 88

Food and Drug Administration Manufacturing Safety Pharmaceutical 88

Pharmaceutical Technology

APRIL 24, 2023

These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52